Terms: = Breast cancer AND BRD4, O60885, 23476, ENSG00000141867, HUNKI, CAP, MCAP AND Clinical Outcome
4 results:
1. A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic breast cancer.
Cescon DW; Hilton J; Morales Murilo S; Layman RM; Pluard T; Yeo B; Park IH; Provencher L; Kim SB; Im YH; Wyce A; Krishnatry AS; Hicks K; Zhang Q; Barbash O; Khaled A; Horner T; Dhar A; Oliveira M; Sparano JA
Clin Cancer Res; 2024 Jan; 30(2):334-343. PubMed ID: 37992310
[TBL] [Abstract] [Full Text] [Related]
2. Tumor stromal nicotinamide N-methyltransferase overexpression as a prognostic biomarker for poor clinical outcome in early-stage colorectal cancer.
Ogawa M; Tanaka A; Namba K; Shia J; Wang JY; Roehrl MHA
Sci Rep; 2022 Feb; 12(1):2767. PubMed ID: 35177765
[TBL] [Abstract] [Full Text] [Related]
3. Tumoral brd4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival.
Lee M; Tayyari F; Pinnaduwage D; Bayani J; Bartlett JMS; Mulligan AM; Bull SB; Andrulis IL
BMC Cancer; 2018 Jul; 18(1):750. PubMed ID: 30029633
[TBL] [Abstract] [Full Text] [Related]
4. Transformation resistance in a premature aging disorder identifies a tumor-protective function of brd4.
Fernandez P; Scaffidi P; Markert E; Lee JH; Rane S; Misteli T
Cell Rep; 2014 Oct; 9(1):248-260. PubMed ID: 25284786
[TBL] [Abstract] [Full Text] [Related]
